Carl Icahn Adds 15% Stake in Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN), How Will Other Investors React?

Former research stage biopharmaceutical company and now surviving off roalyty streams, Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN), announces that Carl Icahn has taken an additional 15% position in the company.

After selling out in the second quarter, Carl Icahn (Trades, Portfolio) acquired an even larger position in Enzon Pharmaceuticals (ENZN) on Nov. 28.

He bought 6,598,886 shares for an average cost of 41 cents per share. This represents nearly 15% of the company’s outstanding shares but only accounts for 0.01% of his total assets managed.

Enzon was formerly a research stage biopharmaceutical company known for its Customized PEGylation Linker Technology. PEGylation is used in the development of drugs to improve characteristics like solubility, reduced dosage, stability and lower toxicity. It now has no clinical operations and very limited corporate operations. Currently, it is surviving off royalty streams from products that incorporate this technology. These products include PegIntron, Sylatron, Macugen and CIMZIA. The company also ran a products and manufacturing division but divested it in 2010.

Management revealed it is expecting to receive a cumulative amount of $21 million in royalty revenues between the beginning of 2016 and 2021. Many expect the company to liquidate after this point. Icahn may be interested in Enzon for this very reason. The company already distributes special dividends throughout the year so its final liquidation may prove to be especially beneficial to shareholders.

The New Jersey-based biopharmaceutical company has a market cap of $19.9 million and an enterprise value of $7.12 million. It has a price-earnings (P/E) ratio of 1.4, a price-book (P/B) ratio of 0.9 and a price-sales (P/S) ratio of 1.9.

GuruFocus ranked the company’s financial strength 8 of 10. The Piotroski F-Score of 5 and Altman Z-Score of 68.12 suggest the company is financially stable. The return on invested capital (ROIC) outperforms the weighted average cost of capital (WACC) so the company is creating value as it grows. In addition, the company has no debt.

In contrast, Enzon’s profitability and growth was ranked 4 of 10 by GuruFocus. It has an operating margin of 78.3% and a net margin of 149.6%. The return on equity (ROE) and return on assets (ROA) outperform 99% of other biotechnology companies. The return on capital (ROC) outperforms 100% of competitors. Where the company falls short is its three-year revenue growth of -24.3%. This figure underperforms 76% of competitors. Additionally, the company has a one-star predictability rating, which means it is hard to predict future results.

The stock reached its all-time high of $77.94 in November of 2000. Since then, the stock has declined significantly. In April of 2002, the stock was trading around $40 and fell to $28.73 by the end of May that same year. From there, the stock continued its gradual decline with only a few surges throughout the next several years. Within the past six years, the highest price the stock has reached was $12.16 on Dec. 31, 2010. It has been trading under $2 since August 2013.

Icahn has a long history with the company that dates back prior to the first quarter of 2010.

Original Source


Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) shares are trading -2.76% on the news and in the range of $0.41 – 0.47 during the current trading session.  When taking a look at which direction the stock might be headed, investors often look to brokerage analysts who cover the stock.  Sell-side research firms on Wall Street currently have a consensus one-year price target of $14.00 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.

Are Shares of Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

Sell-side analysts are projecting earnings per share of $0.00 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $0.03 per share according to First Call.

In looking at where the stock is trading on a technical level, the stock is trading +16.31% away from its 50-day moving average of $0.38.  Based on the most recent available data, the equity is -60.00% off of its 52-week high of $1.10 and +27.54% away from its 52-week low which is $0.34.

In taking a look at the company’s valuation, the firm’s price to earnings ratio stands at 1.22.  This is a crucial indicator investors watch as higher ratios compared to peers, would suggest higher future earnings growth potential for the stock.  Today, the stock opened at $0.46 and the last bid at the time of writing stood at $0.44.  During the session thus far, the equity dipped down to $0.41 and touched $0.47 as the high point.  Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) has a market cap of $19.45M and has seen an average daily volume of 92,445 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below. 

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: Nothing contained in this publication is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Related posts

Leave a Comment